Clinical Efficacy of Modified Shentong Zhuyutang in Treatment of Acute Discogenic Low Back Pain Due to Wind-Cold and Stasis Obstruction Syndrome / 中国实验方剂学杂志

Objective:To evaluate of modified Shentong Zhuyutang combined with celecoxib capsules in the treatment of acute discogenic low back pain due to wind-cold and stasis obstruction sydrome. Method:One hundred and forty eligible patients were randomly divided into control group （70 cases） and observation group （70 cases）. Patients in both groups took the celecoxib capsules orally， 200 mg/time. On this basis， patients in the control group were further treated with Tongluo Huoxue capsule orally， 6 capsules/time， 3 times/day， while those in the observation group received the modified Shentong Zhuyutang， 1 bag/day， for three weeks. The short-form McGillpain questionnaire （SF-MPQ）， including pain rating index （PRI）， present pain intensity （PPI）， and visual analog scale （VAS）， Oswestry disability index （ODI）， wind-cold obstruction and stasis syndrome， and abilities of daily living （ADL） scoring and the Schober's test were conducted before and after treatment. The tumor necrosis factor-<italic>α</italic> （TNF-<italic>α</italic>）， interleukin-1<italic>β</italic> （IL-1<italic>β</italic>）， IL-6， thromboxane B₂ （TXB₂）， and 6-keto prostaglandin F₁<italic>_α</italic> （6-keto-PGF₁<italic>_α</italic>） levels before and after treatment were measured， followed by the safety evaluation. Result:The PRI， VAS， and PPI scores in SF-MPQ of the observation group were reduced in contrast to those in the control group （<italic>P</italic><0.01）. The wind-cold and stasis obstruction syndrome and ODI scores in the observation group also declined as compared with those of the control group （<italic>P</italic><0.01）， while the ADL and Schober's test scores were elevated （<italic>P</italic><0.01）. The TNF-<italic>α</italic>， IL-1<italic>β</italic>， IL-6， and TXB₂ levels in the observation group were lower than those in the control group （<italic>P</italic><0.01）， whereas the 6-keto-PGF₁<italic>_α</italic> was higher （<italic>P</italic><0.01）. The excellent and good rate of the observation group was （51/63） 80.95%， significantly better than （39/63） 61.90% of the control group （<italic>χ</italic>²＝5.601， <italic>P</italic><0.05）. No adverse reactions occurred after the intake of Chinese medicinal prescriptions. Conclusion:The modified Shentong Zhuyutang combined with celecoxib capsules is efficient and safe in inhibiting inflammation， easing back pain， enhancing lumbar spine mobility， and improving the ADL of patients with acute DLBP of wind-cold obstruction syndrome.